Metformin and Aging: What the Research and the TAME Trial Are Testing

Metformin is one of the world's most widely prescribed medicines, a first-line treatment for type 2 diabetes for decades. It is also at the center of a bold idea: that a drug could target aging itself rather than one disease at a time. Here's what the evidence says.

What metformin does

Metformin lowers blood sugar mainly by reducing glucose production in the liver and improving insulin sensitivity. At the cellular level it affects mitochondrial energy production and activates a pathway involving AMPK, an energy sensor. It also influences the gut microbiome and inflammation.

Why scientists think it might affect aging

A 2020 review in Cell Metabolism mapped metformin's effects onto the "hallmarks of aging," a framework of biological processes thought to drive aging, such as inflammation, mitochondrial dysfunction, nutrient sensing and cellular senescence. Metformin appears to touch several of them in lab studies.

Supporting evidence includes:

• Animal studies. Metformin extended lifespan in worms and some mouse studies, though results in mice have been inconsistent.
• Observational data in people with diabetes. Some studies suggested people with diabetes taking metformin had similar or lower mortality than people without diabetes, a striking finding. Later analyses questioned this, pointing to biases in how the comparison groups were selected.
• Lower rates of some diseases. Observational studies associate metformin with lower rates of certain cancers and dementia in people with diabetes, but these associations may be affected by confounding.

The TAME trial

A 2016 paper in Cell Metabolism laid out the rationale for the Targeting Aging with Metformin (TAME) trial. The idea is to test whether metformin delays the onset of a composite of age-related diseases (heart disease, cancer, dementia) and death in older adults without diabetes. If successful, it could establish aging as a target regulators would accept for drug development.

TAME has faced long funding delays. Until results from trials like it are available, metformin's anti-aging effects in healthy people remain unproven.

The exercise trade-off

One important finding for active people: a randomized trial in older adults found that metformin blunted some of the improvements in insulin sensitivity and muscle mitochondrial adaptations from aerobic training, and another trial found it reduced muscle growth from resistance training. Exercise is among the best-proven ways to improve healthspan, so a drug that reduces its benefits is a real concern.

Side effects

Metformin is generally considered safe for people with diabetes, but side effects include:

• Gastrointestinal upset, such as diarrhea and nausea, especially when starting.
• Reduced vitamin B12 absorption with long-term use.
• Rare lactic acidosis, mainly in people with kidney impairment or other risk factors.

A 2022 review in Metabolism titled "Metformin: Is it a drug for all reasons and diseases?" summarized its broad potential while emphasizing the need for rigorous trials before expanding its use.

How it compares with other longevity candidates

Metformin, rapamycin, SGLT2 inhibitors and GLP-1 drugs are all approved drugs studied for aging effects. Each has different evidence and trade-offs. For healthy people, none has been proven to extend lifespan.

Why aging itself is hard to target

One reason the TAME trial matters is regulatory. Drug agencies approve treatments for specific diseases, and aging has not traditionally been treated as a disease. That makes it difficult to design a trial and an approval path for a drug intended to slow aging broadly. TAME's design, measuring a composite of several age-related diseases rather than lifespan itself, was proposed as a workaround that regulators might accept.

If a drug could delay the onset of multiple chronic diseases at once, it would be a major shift in medicine, because most older adults develop several conditions over time and treating each separately has limits. That's the big idea behind "geroscience": targeting shared biological processes rather than individual diseases.

Metformin was chosen as a test case partly because it is inexpensive, widely available, has a long safety record in people with diabetes and has plausible mechanisms. But being a good test case is not the same as being proven. Other candidates, including SGLT2 inhibitors, GLP-1 receptor agonists and rapalogs, are also being studied, and some have stronger outcome data in specific diseases. The broader lesson is that the field is moving toward rigorous trials, which is exactly what is needed to move beyond speculation.

Where this fits in longevity science

Longevity research tries to answer two related questions: how to extend lifespan (how long we live) and how to extend healthspan (how long we live in good health). Much of the field is organized around the "hallmarks of aging," a set of biological processes such as nutrient sensing, mitochondrial function, inflammation and cellular senescence that are thought to drive age-related decline.

The interventions with the strongest human evidence for healthy aging are still behavioral: regular aerobic and strength training, not smoking, healthy body composition, good sleep, a diet built on whole foods, and managing blood pressure, lipids and blood sugar. Drugs and supplements studied for aging, from rapamycin to NAD+ precursors, are being tested against that backdrop. For most of them, the human data are early.

A useful rule of thumb is that anything that sounds like it adds decades to life is almost certainly overstated, while the boring basics quietly have the best data. We try to give you both the exciting science and that honest perspective.

Key terms

• Lifespan: how long an organism lives.
• Healthspan: the years lived in good health, free of serious disease or disability.
• Hallmarks of aging: biological processes believed to drive aging.
• mTOR: a nutrient-sensing pathway that regulates cell growth.
• Autophagy: the process cells use to break down and recycle damaged components.
• Observational study: research that follows people without assigning an intervention; it can show associations but not prove causation.
• Confounding: when a third factor explains an apparent link between two things.
• Meta-analysis: a statistical combination of results from multiple studies.

The bottom line

Metformin is a safe, effective diabetes medicine with intriguing hints of broader anti-aging effects. Those hints come mostly from animal studies and observational data, and it may blunt some benefits of exercise. Large trials are needed before it can be recommended for aging in healthy people. Talk to a physician before considering it for any purpose.

How to evaluate a new claim on this topic

New studies, podcasts and social posts appear every week. Before acting on any of them, run the claim through a quick checklist:

1. Find the original study. Search the title or author on PubMed. If a claim can't be traced to a published paper, treat it as opinion.
2. Check the species. Cell, worm and mouse studies generate ideas; human trials test them. Many promising animal findings never replicate in people.
3. Look for a control group. Without a placebo or comparison group, it is impossible to separate the effect of the intervention from time, expectation or other changes.
4. Note the size and length. Small, short studies are useful signals but frequently overturned by larger, longer ones.
5. Look at the outcome. A change in a lab marker is not the same as feeling better, performing better or living longer.
6. Ask who funded it. Industry funding doesn't make a study wrong, but it is a reason to look for independent replication.
7. Read the side-effect section. "No serious adverse events" in 30 people over 8 weeks says little about long-term safety.
8. Ask what it would replace. The best-proven basics, such as sleep, strength training, aerobic fitness and diet quality, usually deliver more than any single add-on.

If a claim survives that checklist, it is worth discussing with a qualified clinician who knows your history.

Frequently asked questions

Does metformin slow aging?

It hasn't been proven in humans. Trials like TAME aim to test whether it delays age-related diseases.

Should healthy people take metformin for longevity?

There is no evidence supporting this, and it may blunt exercise benefits. Discuss with a physician.

Does metformin interfere with exercise?

Some trials show it reduces certain training adaptations in older adults.

What is the TAME trial?

A proposed trial testing whether metformin delays multiple age-related diseases in older adults without diabetes.

What are metformin's common side effects?

Mostly gastrointestinal upset and reduced vitamin B12 absorption over time.

Sources

• Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab, 2020. PubMed 32333835
• Metformin as a Tool to Target Aging. Cell Metab, 2016. PubMed 27304507
• The Anti-Aging Mechanism of Metformin: From Molecular Insights to Clinical Applications. Molecules, 2025. PubMed 40005128
• Metformin: Is it a drug for all reasons and diseases?. Metabolism, 2022. PubMed 35640743

Medical disclaimer

This article is for general educational purposes only and is not medical advice. It does not provide dosing instructions and should not be used to diagnose, treat or prevent any condition. Many compounds discussed on this site are not approved for human use, and some are prohibited in tested sport. Always talk to a licensed physician or other qualified health professional before starting, stopping or changing any medication, supplement, diet or training program. Morpheus Research Learn is an educational hub: nothing on these pages is an offer to sell any peptide, drug or supplement, and nothing here is a recommendation to use one.

Sourcing for your lab? See Morpheus Research's third-party tested research peptides.